What I found interesting in the 10Q In the "Res
Post# of 30066
Posted On: 11/07/2014 10:14:38 PM
What I found interesting in the 10Q
In the "Research Agreements" section, we entered an agreement utilizing a "proprietary compound" while the other agreements with Buck and Miami specifically state MANF. Are we by chance researching something else other than MANF with WashU and Urano?? maybe something to do with small molecules??
Or was this agreement old.. so MANF was "top secret"
Research Agreements--
The Company and The Washington University (“WashU”) entered into a sponsored research agreement whereby the Company is required to pay a total amount of $120 for an employee of WashU to perform certain research utilizing a proprietary compound of the Company’s subject to certain terms and restrictions as further described in the Agreement.
On August 5, 2014, the Company entered into a sponsored research agreement (the “Research Agreement”) with the Buck Institute for Research on Aging pursuant to which Dr. Heinrich Jasper shall perform certain research utilizing Mesencephalic-Astrocyte-derived Neurotrophic Factor (“MANF”), subject to certain terms and restrictions as further described in the Research Agreement.
On October 1 2014, the Company entered into a sponsored research agreement (the “Agreement”) with the University of Miami on the use of MANF in retinal disorders. The agreement calls for three equal payments of $52 on October 30, 2014, April 1, 2015 and upon receipt of the final written report.
In the "Research Agreements" section, we entered an agreement utilizing a "proprietary compound" while the other agreements with Buck and Miami specifically state MANF. Are we by chance researching something else other than MANF with WashU and Urano?? maybe something to do with small molecules??
Or was this agreement old.. so MANF was "top secret"
Research Agreements--
The Company and The Washington University (“WashU”) entered into a sponsored research agreement whereby the Company is required to pay a total amount of $120 for an employee of WashU to perform certain research utilizing a proprietary compound of the Company’s subject to certain terms and restrictions as further described in the Agreement.
On August 5, 2014, the Company entered into a sponsored research agreement (the “Research Agreement”) with the Buck Institute for Research on Aging pursuant to which Dr. Heinrich Jasper shall perform certain research utilizing Mesencephalic-Astrocyte-derived Neurotrophic Factor (“MANF”), subject to certain terms and restrictions as further described in the Research Agreement.
On October 1 2014, the Company entered into a sponsored research agreement (the “Agreement”) with the University of Miami on the use of MANF in retinal disorders. The agreement calls for three equal payments of $52 on October 30, 2014, April 1, 2015 and upon receipt of the final written report.
(0)
(0)